Clinical Trial: Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

Brief Summary: This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

Detailed Summary: This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. All were submitted to a local treatment with Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average). All subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.If positive biopsy (residue tumor) cases will managed with surgery.
Sponsor: University of Sao Paulo

Current Primary Outcome: post-treatment biopsy [ Time Frame: post-treatment biopsy ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Sao Paulo

Dates:
Date Received: December 3, 2008
Date Started: December 2008
Date Completion: February 2013
Last Updated: June 12, 2012
Last Verified: June 2012